Assessment of safety and effectiveness: the clinical use of tofogliflozin in patients with type 2 diabetes mellitus
Phase of Trial: Phase IV
Latest Information Update: 06 Feb 2019
Price : $35 *
At a glance
- Drugs Tofogliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Acronyms AYUMI
- 26 Jan 2019 Status changed from active, no longer recruiting to completed.
- 16 May 2018 Status changed from recruiting to active, no longer recruiting.
- 27 Sep 2016 Planned End Date changed from 14 Dec 2017 to 31 Aug 2018.